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Background: Fabry disease is an X-linked inherited metabolic condition where the deficit of the α-galactosidase A
enzyme, encoded by the GLA gene, leads to glycosphingolipid storage, mainly globotriaosylceramide. To date,
more than 600 mutations have been identified in human GLA gene that are responsible for FD, including missense
and nonsense mutations, small and large deletions. Such mutations are usually inherited, and cases of de novo
onset occur rarely.
Case presentation: In this article we report an interesting case of a 44-year-old male patient suffering from a
severe form of Fabry disease, with negative family history. The patient showed signs such as cornea verticillata,
angiokeratomas, cardiac and neurological manifestations, an end-stage renal disease and he had low α-galactosidase A
activity. We detected, in this subject, the mutation c.493 G > C in the third exon of the GLA gene which causes the
amino acid substitution D165H in the protein. This mutation affects the amino acid - belonging to the group of
buried residues - involved, probably, in the preservation of the protein folding. Moreover, studies of multiple sequence
alignment indicate that this amino acid is highly conserved, thus strengthening the hypothesis that it is a key amino
acid to the enzyme functionality.
The study of the relatives of the patient showed that, surprisingly, none of the members of his family of origin had this
genetic alteration, suggesting a de novo mutation. Only his 11-year-old daughter - showing acroparaesthesias and heat
intolerance with reduced enzymatic activity - had the same mutation.
Conclusions: We suggest that a non-inherited mutation of the α-galactosidase A gene is responsible for Fabry disease
in the patient who had reduced enzyme activity and classical clinical manifestations of the disease. In a family, it is rare
to find only one Fabry disease affected subject with a de novo mutation. These findings emphasize the importance of
early diagnosis, genetic counselling, studying the genealogical tree of the patients and starting enzyme replacement
therapy to prevent irreversible vital organ damage that occurs during the course of the disease.
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Anderson-Fabry disease (OMIM 301500), or Fabry disease
(FD), is an X-linked inherited metabolic condition charac-
terized by a deficit in the activity of the α-galactosidase A
enzyme, encoded by the GLA gene, which leads to glyco-
sphingolipid storage, mainly globotriaosylceramide (Gb3)
[1]. FD is one of the most important sphingolipidoses and
it is considered a rare disease, with an incidence of 1 in* Correspondence: duro@ibim.cnr.it
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reproduction in any medium, provided the or40,000, though it is probably more frequent than com-
monly believed [2,3]. The clinical manifestations are se-
verer in hemizygous male subjects than in heterozygous
female subjects, who are sometimes completely asymp-
tomatic, in accordance with Lyon hypothesis of random
X-chromosome inactivation [2,4]. To date, more than 600
mutations have been identified in human GLA gene that
are responsible for FD, including missense and nonsense
mutations, small and large deletions (Human Gene Muta-
tion Database, www.hgmd.org). Such mutations are usually
inherited and cases of de novo onset, i.e. arisen sponta-
neously, occur rarely [5].Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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of cells within many tissues is responsible for the systemic
nature of the disease. Clinical manifestations of Fabry dis-
ease start in childhood, and life-threatening renal, cardiac
and cerebrovascular complications typically arise in adult-
hood [6,7]. Selective damage of epithelial tubular cells and
glomerular epithelial cells induces chronic renal disease,
with progression to end-stage renal disease (ESRD) as the
patient gets older. ESRD generally appears during the
third/fourth decade of life in hemizygous males. Fabry pa-
tients who developed ESRD can be treated with peritoneal
dialysis or haemodialysis, and kidney transplantation from
living and cadaver donors [8]. Enzyme replacement ther-
apy (ERT) provides beneficial effects, by reducing Gb3
storage and preventing its further accumulation [8,9]. ERT
is the current therapy, available for Fabry patients, and it
consists of the intravenous infusion of synthetic enzyme.
In most cases, it blocks the progression of the disease but
it is not able to treat some symptoms. So it is important to
diagnose early in the patient the disease and start the ther-
apy, in order to prevent the most harmful consequences of
the disease [10,11].
We report the case of a 44-year-old man affected by
Fabry disease. He suffered from a severe clinical form of
the disease, at the age of 40 he developed ESRD and he
underwent kidney transplant at 42. We detected a de
novo mutation in the codon 165 of the GLA gene of the
patient, but neither his mother nor his mother’s relatives
had this mutation. His daughter harboured also the same
mutation and showed the clinical manifestations of the
disease typical of childhood [12]. The affected subjects
underwent both enzyme replacement therapy.
Case presentation
A 44-year-old man with systemic manifestations came to
our neurology unit because of a stroke. The analysis of his
medical history revealed that, during childhood, he showed
high rate of antistreptolysin O (ASO) titer, and he fre-
quently suffered from acroparaesthesias, hypohidrosis, joint
pains, cold and heat intolerance and attacks of fever.
At 18, whorled opacities in the cornea (cornea verticil-
lata) were first observed.
At 19, the early manifestations of periumbilical and
genital angiokeratomas appeared.
At 37, clinical and laboratory tests confirmed the pres-
ence of acute articular rheumatism. At the same age, he
manifested episodes of vertigo, tinnitus, hearing impair-
ment and sudden deafness which were believed to be
caused by a neurinoma; however, this was not confirmed
by magnetic resonance imaging (MRI).
At 40, hypertrophic cardiomyopathy and mitral valve in-
sufficiency, proteinuria and a reduced creatinine clearance
rate were observed. He underwent renal biopsy. Light mi-
croscopy examination of the renal biopsy revealed non-specific findings: segmental increases in mesangial cellu-
larity and mesangial matrix were seen in 3/24 of the glom-
eruli. On physical examination, his blood pressure was
140/90 mmHg with a regular pulse rate.
From 37 to 42, the patient had four episodes of vertebro-
basilar transient ischaemic attack. At 40, he underwent a
complete diagnostic work-up, which revealed multiorgan
involvement: damages in the CNS with silent ischemic
strokes, both cortical and subcortical, and severe peripheral
neuropathy; cardiac hypertrophy, altered repolarisation and
right bundle branch block; regarding eyes, cornea verticil-
lata was confirmed; renal involvement with kidney failure
(stage II/DOQI CKD). Selective damage of epithelial cells
and glomerular epithelial cells induced chronic renal dis-
ease with progression to ESRD. The same year, he started
haemodialysis, and at 42 he underwent kidney transplant
from a cadaver donor which normalised his kidney func-
tion. Because of all the clinical manifestations, the presence
of Fabry disease was suspected and genetic and enzymatic
analyses were performed. Peripheral blood sample was
collected and DNA was extracted using the GenElute
Blood Genomic DNA Kit (Sigma-Aldrich, USA). A pre-
sequencing screening was performed on DNA sample by
high resolution melting (HRM) analysis using the Light
Cycler 480 system (Roche Applied Science, Germany)
[13]. Purified PCR mutated products were sequenced
using LI-COR NEN Model 4300 DNA Analyzer, according
to the LI-COR protocol. Sequence analysis of the GLA
gene in the patient, in comparison with the wild-type se-
quence (Figure 1), revealed a single nucleotide point muta-
tion in hemizygosis at nucleotide c.493 G > C in exon 3
(D165H in the protein) [14]. The α-galactosidase A activ-
ity of the patient was determined by Dried Blood Filter
Paper test described by Chamoles et al., with minor modi-
fications [15]: enzyme activity in the whole blood was
0.5 nmol/h/ml (normal range is > 3.0 nmol/h/ml). We ex-
tended the genetic analysis to the family members of the
patient (mother, sister and brother) (Figure 2) and none of
them had any alteration in the GLA gene, suggesting a de
novo mutation in the patient.
The 11-year-old daughter of the patient showed clinical
manifestations referable to Fabry disease, too. She had
severe acroparaesthesias, gastrointestinal symptoms, heat
intolerance and the early signs of renal involvement (pro-
teinuria). The results of the blood tests were in the normal
range. Kidney B-mode ultrasound and color Doppler
ultrasound failed to show significant discrepancies. Liver
ultrasound was normal. The result of ophthalmological
exams and the study of retinal funds were within the
norm. Echocardiogram showed heart size, morphology,
and function to be normal. Brain MRI was normal. Gen-
etic and enzymatic studies were also performed on this
subject: genetic analysis showed she had the same muta-









Figure 1 Alignment of gene sequences. Portion of the sequence of exon 3 of the GLA gene in Patient 2 (forward and reverse strands of the
subject) aligned with the corresponding sequence of a healthy control (wt). The red arrow indicates the position of the mutation c.493 G > C
(D165H in the protein). On the left, the sequencing gel image is shown.
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below the normal range (1 nmol/h/ml).
Both patients, the proband and his daughter, started
ERT: the father had significant beneficial effects only on
his acroparaesthesias and angiokeratomas; the daughter
had marked clinical benefits on all manifestations thanks
to the early diagnosis, according to literature [11].Hemizygous de novo mutation
Heterozygous mutation
Wild Type
Clinical manifestations of Fabry disease 
Figure 2 Genealogical tree of the family of the patient. The
male patient (striped square) is the only member of its family of
origin who had the mutation. In the next generation, his daughter
harboured also the same mutation in heterozygosis (dotted circle).Discussion
Fabry disease is a rare pathology and significant thera-
peutic progress have been done in recent years. The het-
erogeneity of its manifestations causes a high degree of
variation in its clinical symptoms, both in hemizygous
and heterozygous.
In this paper we report the case of two members of
one family - having the classic form of Fabry disease - in
which the sequence analysis of the GLA gene, in com-
parison with the wild-type sequence, revealed a single
nucleotide point mutation (hemizygous and heterozy-
gous) at nucleotide c.493 G > C in exon 3. This mutation
results in the replacement of an amino acid (aspartic
acid) by a basic one (histidine) at codon 165, thus alter-
ing normal α-galactosidase A activity. This genetic alter-
ation was previously described, in a Hungarian family, as
associated with the classic form of Fabry disease [14].
The D165 amino acid belongs to the group of buried
amino acids, so probably it is involved in the preserva-
tion of the protein folding, as reported in literature
[14,16]. Moreover, we believe that this amino acid and
the flanking ones have a key role in the enzyme func-
tionality, as revealed also by the multiple sequence align-
ment, which shows that they have been highly conserved
throughout the evolution (Figure 3). Our hypothesis is
strengthened by the fact that the mutations affecting this
amino acid (D165H e D165V) and some of the flanking
ones (G163V, L166G e L166V) are responsible for the
classic phenotype of Fabry disease [14,17-20]. Moreover,
the study of the potential role of this mutation, per-
formed using PolyPhen-2 software, confirms the dam-
aging effect on the enzyme structure.
Figure 3 Phylogenetic conservation of wild-type human α-Gal
A amino acids. Alignment of wild-type human α-Gal A amino acids
with other organisms. The rectangle indicates the position of the
amino acid that was found mutated in the patient.
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prisingly, that none of his family members (mother, sis-
ter or brother) was affected by the disease; all of them
showed normal enzymatic activity and the wild-type
GLA gene. This indicated that the disease was caused by
a de novo mutation, arisen spontaneously in this male
patient. To confirm these findings, the analysis of the
genetic profile of the patient and his relatives was carried
out, proving that they had a family relationship. In a
family, it is rare to find only one Fabry disease affected
subject with a de novo mutation [21].Conclusion
In conclusion, we suggest that a non-inherited muta-
tion of the α-galactosidase A gene is responsible for
Fabry disease in the patient, who had reduced enzyme
activity and classical signs of the disease, such as typ-
ical skin lesions, corneal opacities, and cardiac, renal
and neurological manifestations. These findings emphasize
the importance of early diagnosis, genetic counselling,
studying the genealogical tree of the patients and starting
the enzyme replacement therapy to prevent irreversible
vital organ damage that occurs during the course of the
disease.Consent
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for the publication of these data and any accompanying
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